Explore more publications!
Technology Reporter Denmark
Submit Press Release

Technology Reporter Denmark Press Releases

Labels On
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
Info
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 7, 2025

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Indeterminate GlobeNewswire, Inc.
Copenhagen Infrastructure Partners acquires first biogas plant in the UK
October 31, 2025

Copenhagen Infrastructure Partners acquires first biogas plant in the UK

Indeterminate GlobeNewswire, Inc.
Prepared Food Equipment Market Set to Reach USD 31.02 Billion by 2034, Driven by Technological Innovations and Rising Demand for Convenience Foods
November 5, 2025

Prepared Food Equipment Market Set to Reach USD 31.02 Billion by 2034, Driven by Technological Innovations and Rising Demand for Convenience Foods

Indeterminate GlobeNewswire, Inc.
BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta
November 3, 2025

BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta

Indeterminate GlobeNewswire, Inc.
Kubbco Launches Wellfluence: The First Compliant Patient Creator Network for Authentic Life Sciences Marketing
November 3, 2025

Kubbco Launches Wellfluence: The First Compliant Patient Creator Network for Authentic Life Sciences Marketing

Neutral EIN Presswire
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
November 3, 2025

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Indeterminate GlobeNewswire, Inc.
Exosome Research Market Size to Reach USD 961.41 Million by 2034
November 3, 2025

Exosome Research Market Size to Reach USD 961.41 Million by 2034

Indeterminate GlobeNewswire, Inc.
Bone Marrow Transplant Market to Hit USD 16.76 Billion by 2034, Driven by Advances in Transplant Technology and Rising Hematologic Disorders
November 3, 2025

Bone Marrow Transplant Market to Hit USD 16.76 Billion by 2034, Driven by Advances in Transplant Technology and Rising Hematologic Disorders

Indeterminate GlobeNewswire, Inc.
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding
October 31, 2025

Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding

Indeterminate GlobeNewswire, Inc.
CDMO Services Market for Pharma and Biotech: Growth Outlook and Industry Insights (2024–2034)
October 31, 2025

CDMO Services Market for Pharma and Biotech: Growth Outlook and Industry Insights (2024–2034)

Indeterminate GlobeNewswire, Inc.
Researchers Identify Genetic Cause Behind Alzheimer’s Increased Risk
October 23, 2025

Researchers Identify Genetic Cause Behind Alzheimer’s Increased Risk

Indeterminate MENAFN
Owner: Sawsan Dababneh & Ramzi AbdelJaber

MENAFN

Indeterminate
Owned By Sawsan Dababneh & Ramzi AbdelJaber through The Middle East North Africa Financial Network, Inc
Year Founded 2000
Website menafn.com
Domain Registration Year Indeterminate
Access Type open
Publication Location Amman, New York, Dubai

We welcome your feedback!
If you have comments or corrections, let us know.

Clinical Trial Imaging Market to Reach USD 5.58 Billion by 2034, Driven by Growing Adoption of Advanced Imaging Technologies
October 30, 2025

Clinical Trial Imaging Market to Reach USD 5.58 Billion by 2034, Driven by Growing Adoption of Advanced Imaging Technologies

Indeterminate GlobeNewswire, Inc.
Battery Technology Market Size Worth USD 256.08 Billion by 2034
October 28, 2025

Battery Technology Market Size Worth USD 256.08 Billion by 2034

Indeterminate GlobeNewswire, Inc.
Life Science CDMO Market Outlook 2025–2034: Trends, Growth Drivers and Regional Insights
October 28, 2025

Life Science CDMO Market Outlook 2025–2034: Trends, Growth Drivers and Regional Insights

Indeterminate GlobeNewswire, Inc.
Molecular Spectroscopy Market to Reach USD 9.04 Billion by 2034, Driven by Expanding Healthcare Applications and Research Growth
October 28, 2025

Molecular Spectroscopy Market to Reach USD 9.04 Billion by 2034, Driven by Expanding Healthcare Applications and Research Growth

Indeterminate GlobeNewswire, Inc.
BIO-key International and IT2Trust Partner to Strengthen IAM and Biometric Security Across the Nordic Region of Denmark, Sweden, Norway and Finland
October 27, 2025

BIO-key International and IT2Trust Partner to Strengthen IAM and Biometric Security Across the Nordic Region of Denmark, Sweden, Norway and Finland

Indeterminate GlobeNewswire, Inc.
Canadian scientists describe an extinct rhino species from Canada’s High Arctic
October 28, 2025

Canadian scientists describe an extinct rhino species from Canada’s High Arctic

Indeterminate GlobeNewswire, Inc.
New Research Reveals How Electric Car Sounds Are Changing the Driving Experience
October 27, 2025

New Research Reveals How Electric Car Sounds Are Changing the Driving Experience

Neutral EIN Presswire
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
October 27, 2025

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Indeterminate GlobeNewswire, Inc.
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
October 20, 2025

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions